

# Valeant Pharmaceuticals Announces Offering Of \$1.45 Billion Of Common Shares

March 16, 2015

LAVAL, Quebec, March 16, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced today that it has filed with the U.S. Securities and Exchange Commission a preliminary prospectus supplement to its effective shelf registration statement on Form S-3 in connection with a registered offering in the United States of \$1.45 billion of its common shares (the "Offering").

The Company will also grant to the underwriter of the Offering an option, exercisable for a period of 30 days following the date of the final prospectus supplement, to purchase additional common shares equal to up to 15% of the common shares initially sold.

The Company expects to use the net proceeds of the offering, together with borrowings under the Company's incremental term loan facilities, the proceeds of an offering of the Company's senior notes and cash on hand, to fund the purchase price of the previously announced acquisition of Salix Pharmaceuticals, Ltd. ("Salix"), as well as repayments of indebtedness of Salix and certain transaction expenses. The Company intends to use any remaining proceeds for general corporate purposes, including acquisitions and debt repayments.

Deutsche Bank Securities Inc. will act as bookrunning manager for the Offering.

A copy of the preliminary prospectus supplement and accompanying prospectus relating to the Offering in the United States (the "Prospectus") will be available on EDGAR at

[www.sec.gov](http://www.sec.gov)

. Alternatively, a copy of the Prospectus may be obtained from Deutsche Bank Securities Inc., Attention: Prospectus Group at 60 Wall Street, New York, NY 10005-2836, telephone: 1-800-503-4611, email:

[prospectus.CPDG@db.com](mailto:prospectus.CPDG@db.com)

. The common shares have not been and will not be qualified for sale to the public by prospectus under applicable Canadian securities laws and the common shares may not be offered or sold to any purchaser located or resident in any province or territory of Canada.

This press release shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The Offering is subject to customary stock exchange approvals.

## **About Valeant**

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology, and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at

[www.valeant.com](http://www.valeant.com)

## **Caution Regarding Forward-Looking Information and "Safe Harbor" Statement**

This press release may contain forward-looking statements, including, but not limited to, our financing plans and the use of proceeds of the proposed offering, the consummation of the proposed acquisition of Salix, and the repayment and redemption of indebtedness of Salix. Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in our most recent annual and quarterly reports and detailed from time to time in our other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which risks and uncertainties are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. We undertake no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes, except as required by law.

### Contact Information:

Laurie W. Little  
Valeant Pharmaceuticals International, Inc.  
949-461-6002  
[laurie.little@valeant.com](mailto:laurie.little@valeant.com)

### Media:

Renee E. Soto / Meghan Gavigan  
Sard Verbinnen & Co.  
212-687-8080  
[rsoto@sardverb.com](mailto:rsoto@sardverb.com)  
/ [mgavigan@sardverb.com](mailto:mgavigan@sardverb.com)

To view the original version on PR Newswire, visit:

<http://www.prnewswire.com/news-releases/valeant-pharmaceuticals-announces-offering-of-145-billion-of-common-shares-300051145.html>

SOURCE Valeant Pharmaceuticals International, Inc.

### Investor Inquiries

[ir@bauschhealth.com](mailto:ir@bauschhealth.com)  
877-281-6642  
514-856-3855 (Canada)

[LEGAL NOTICE](#)

[PRIVACY POLICY](#)

[EMAIL ALERTS](#)

[EMAIL PAGE](#)



### Media inquiries

[Corporate.communications@bauschhealth.com](mailto:Corporate.communications@bauschhealth.com)  
908-569-3692

Use of this site signifies your agreement to  
the Legal Notice and Privacy Policy.

©2026 Bausch Health Companies Inc. All rights  
reserved. MTB.0230.USA.18 V2.0

CALIFORNIA RESIDENTS: DO NOT SELL MY  
PERSONAL INFORMATION

